Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  AMAG Pharmaceuticals, Inc.    AMAG

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/19/2017 06/20/2017 06/21/2017 06/22/2017 06/23/2017 Date
16.65(c) 16.85(c) 17.75(c) 18.2(c) 18.35(c) Last
903 417 752 740 1 423 656 918 882 981 108 Volume
+1.52% +1.20% +5.34% +2.54% +0.82% Change
More quotes
Financials ($)
Sales 2017 648 M
EBIT 2017 88,4 M
Net income 2017 22,8 M
Debt 2017 591 M
Yield 2017 -
Sales 2018 546 M
EBIT 2018 35,7 M
Net income 2018 -13,6 M
Debt 2018 617 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 1,91x
EV / Sales2018 2,31x
Capitalization 643 M
More Financials
Company
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia.It focuses on the development and commercialization of Feraheme injection for intravenous or IV, use to treat iron... 
Sector
Pharmaceuticals
Calendar
07/27Earnings Release
More about the company
Surperformance© ratings of AMAG Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on AMAG PHARMACEUTICALS, INC.
06/08 AMAG PHARMACEUTICALS : Stock Performance Review on Healthcare Sector -- Palatin ..
06/01 AMAG Announces First Patient Enrolled in Phase 2b/3a Digoxin Immune Fab Study..
06/01 AMAG PHARMACEUTICALS : to Present at Upcoming Investor Conferences
05/31 AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
05/24 AMAG PHARMACEUTICALS, INC. (NASDAQ : AMAG) Files An 8-K Departure of Directors o..
05/24 AMAG PHARMACEUTICALS INC. : Change in Directors or Principal Officers, Submissio..
05/16 AMAG PHARMACEUTICALS : Completes Financing Transactions in Support of Future Gro..
05/16 AMAG Pharmaceuticals Appoints Helen Milton, Ph.D. as Vice President of Regula..
05/15 AMAG PHARMACEUTICALS,INC. (NASDAQ : AMAG) Files An 8-K Entry into a Material Def..
05/15 AMAG PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Terminat..
More news
Sector news : Pharmaceuticals - NEC
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/23 China's ICBC says checks of loans to big acquirers are routine
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
More sector news : Pharmaceuticals - NEC
Latest Tweets
10:56aFirst Trust Advisors LP Raises Stake in AMAG Pharmaceuticals, Inc. $AMAG  
06/22AMAG Pharmaceuticals, Inc. $AMAG Shares Bought by Comerica Bank  
06/22Brokerages Set AMAG Pharmaceuticals, Inc. $AMAG PT at $25.67  
06/21AMAG Pharmaceuticals, Inc. $AMAG Stake Held by Palo Alto Investors LLC  
06/19AMAG Pharmaceuticals $AMAG Receives Daily News Impact Score of 0.10  
More tweets
Qtime:17
News from SeekingAlpha
06/07 AMAG Pharmaceuticals (AMAG) Presents At Jefferies 2017 Global Healthcare Conf..
05/25 AMAG Pharmaceuticals (AMAG) Investor Presentation - Slideshow
05/12 AMAG Pharma gets credit rating upgrade; shares +1.8%
05/04 AMAG Pharma down more than 7% on capital raise
05/02 AMAG Pharmaceuticals' (AMAG) CEO Bill Heiden on Q1 2017 Results - Earnings Ca..
Advertisement
Chart AMAG PHARMACEUTICALS, INC.
Duration : Period :
AMAG Pharmaceuticals, Inc. Technical Analysis Chart | AMAG | US00163U1060 | 4-Traders
Full-screen chart
Technical analysis trends AMAG PHARMACEUTIC...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Average target price 26,0 $
Spread / Average Target 42%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
William K. Heiden President, Chief Executive Officer & Director
Gino Santini Chairman
Edward H. Myles Chief Financial Officer, Treasurer & Senior VP
Julie Krop Chief Medical Officer & SVP-Regulatory Affairs
Nathan McBride Chief Information Officer & Senior VP-Innovation
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMAG PHARMACEUTICALS, ..-47.27%643
JOHNSON & JOHNSON18.42%367 520
NOVARTIS13.09%225 386
ROCHE HOLDING LTD.8.68%224 497
PFIZER5.20%203 487
MERCK AND COMPANY12.38%180 958
More Results